JP2007514639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514639A5 JP2007514639A5 JP2006516322A JP2006516322A JP2007514639A5 JP 2007514639 A5 JP2007514639 A5 JP 2007514639A5 JP 2006516322 A JP2006516322 A JP 2006516322A JP 2006516322 A JP2006516322 A JP 2006516322A JP 2007514639 A5 JP2007514639 A5 JP 2007514639A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- hydrogen atom
- independently selected
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 9
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical group FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- -1 cyano, amino Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 150000001721 carbon Chemical class 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 102000007588 cdc25 Phosphatases Human genes 0.000 claims 1
- 108010046616 cdc25 Phosphatases Proteins 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0307649A FR2856688B1 (fr) | 2003-06-25 | 2003-06-25 | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| PCT/FR2004/001586 WO2005000852A2 (fr) | 2003-06-25 | 2004-06-24 | Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009091214A Division JP2009149694A (ja) | 2003-06-25 | 2009-04-03 | 少なくとも１の他の抗癌剤と組み合わせた少なくとも１のＣｄｃ２５ホスファターゼ阻害剤を含有する製品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007514639A JP2007514639A (ja) | 2007-06-07 |
| JP2007514639A5 true JP2007514639A5 (enExample) | 2007-08-09 |
Family
ID=33515382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516322A Pending JP2007514639A (ja) | 2003-06-25 | 2004-06-24 | 少なくとも１の他の抗癌剤と組み合わせた少なくとも１のＣｄｃ２５ホスファターゼ阻害剤を含有する製品 |
| JP2009091214A Pending JP2009149694A (ja) | 2003-06-25 | 2009-04-03 | 少なくとも１の他の抗癌剤と組み合わせた少なくとも１のＣｄｃ２５ホスファターゼ阻害剤を含有する製品 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009091214A Pending JP2009149694A (ja) | 2003-06-25 | 2009-04-03 | 少なくとも１の他の抗癌剤と組み合わせた少なくとも１のＣｄｃ２５ホスファターゼ阻害剤を含有する製品 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060281736A1 (enExample) |
| EP (3) | EP1792905A1 (enExample) |
| JP (2) | JP2007514639A (enExample) |
| AR (2) | AR044930A1 (enExample) |
| AT (1) | ATE439836T1 (enExample) |
| CA (1) | CA2530668A1 (enExample) |
| DE (1) | DE602004022674D1 (enExample) |
| DK (1) | DK1641453T3 (enExample) |
| ES (1) | ES2332137T3 (enExample) |
| FR (1) | FR2856688B1 (enExample) |
| MX (1) | MXPA06000216A (enExample) |
| MY (1) | MY141725A (enExample) |
| PL (1) | PL1641453T3 (enExample) |
| WO (1) | WO2005000852A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2834289B1 (fr) | 2001-12-27 | 2004-03-19 | Sod Conseils Rech Applic | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
| ATE368654T1 (de) * | 2001-12-27 | 2007-08-15 | Sod Conseils Rech Applic | Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren |
| FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| DE10353792A1 (de) | 2003-11-13 | 2005-06-23 | Exner, Heinrich, Dr.med.vet. | Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion |
| FR2877667B1 (fr) | 2004-11-05 | 2007-03-23 | Sod Conseils Rech Applic | Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques |
| FR2879598B1 (fr) | 2004-12-17 | 2007-03-30 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
| FR2879460B1 (fr) * | 2004-12-17 | 2007-02-23 | Sod Conseils Rech Applic | Associations anti-douleur comprenant un derive de dihydroimidazopyrazine |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8222342B2 (en) * | 2007-09-06 | 2012-07-17 | Basf Se | Blends from branched polyaryl ethers and hydrophilic polymers |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| JO3156B1 (ar) | 2009-07-09 | 2017-09-20 | Novartis Ag | ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا |
| HUE042801T2 (hu) | 2010-11-12 | 2019-07-29 | Pharma Mar Sa | Kombinációs terápia mitózisgátlóval |
| TWI791515B (zh) | 2017-04-24 | 2023-02-11 | 瑞士商諾華公司 | 治療療法 |
| US20210106567A1 (en) * | 2019-10-01 | 2021-04-15 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for inhibiting carp-1 binding to nemo |
| PH12022551216A1 (en) | 2019-11-21 | 2023-07-17 | Pharma Mar Sa | Methods of treating small cell lung cancer with lurbinectedin formulations |
| US11981645B1 (en) | 2023-10-10 | 2024-05-14 | King Faisal University | N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US735674A (en) * | 1902-01-29 | 1903-08-04 | William C Matthias | Sparking igniter for explosive-engines. |
| FR50000E (fr) | 1938-11-29 | 1939-09-29 | Moulin à café | |
| US5523430A (en) * | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
| US6673927B2 (en) * | 1996-02-16 | 2004-01-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farnesyl transferase inhibitors |
| US6383871B1 (en) * | 1999-08-31 | 2002-05-07 | Micron Technology, Inc. | Method of forming multiple oxide thicknesses for merged memory and logic applications |
| EP1233787B8 (fr) * | 1999-11-09 | 2005-05-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| FR2812198B1 (fr) * | 2000-07-28 | 2008-07-18 | Sod Conseils Rech Applic | DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25 |
| CA2432417A1 (fr) * | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| FR2825278A1 (fr) * | 2001-05-30 | 2002-12-06 | Sod Conseils Rech Applic | Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| AR037714A1 (es) * | 2001-12-06 | 2004-12-01 | Maxia Pharmaceuticals Inc | Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer |
| FR2834289B1 (fr) * | 2001-12-27 | 2004-03-19 | Sod Conseils Rech Applic | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
| ATE368654T1 (de) * | 2001-12-27 | 2007-08-15 | Sod Conseils Rech Applic | Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren |
| FR2856686A1 (fr) * | 2003-06-25 | 2004-12-31 | Sod Conseils Rech Applic | Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation |
| FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| JP4273056B2 (ja) * | 2004-08-12 | 2009-06-03 | 不二越機械工業株式会社 | 研磨装置 |
-
2003
- 2003-06-25 FR FR0307649A patent/FR2856688B1/fr not_active Expired - Fee Related
-
2004
- 2004-06-17 MY MYPI20042361A patent/MY141725A/en unknown
- 2004-06-24 DK DK04767442T patent/DK1641453T3/da active
- 2004-06-24 WO PCT/FR2004/001586 patent/WO2005000852A2/fr not_active Ceased
- 2004-06-24 JP JP2006516322A patent/JP2007514639A/ja active Pending
- 2004-06-24 DE DE602004022674T patent/DE602004022674D1/de not_active Expired - Lifetime
- 2004-06-24 EP EP07006144A patent/EP1792905A1/fr not_active Withdrawn
- 2004-06-24 PL PL04767442T patent/PL1641453T3/pl unknown
- 2004-06-24 AT AT04767442T patent/ATE439836T1/de not_active IP Right Cessation
- 2004-06-24 EP EP04767442A patent/EP1641453B1/fr not_active Expired - Lifetime
- 2004-06-24 CA CA002530668A patent/CA2530668A1/fr not_active Abandoned
- 2004-06-24 US US10/562,625 patent/US20060281736A1/en not_active Abandoned
- 2004-06-24 EP EP08020152A patent/EP2335702A1/fr not_active Withdrawn
- 2004-06-24 MX MXPA06000216A patent/MXPA06000216A/es active IP Right Grant
- 2004-06-24 ES ES04767442T patent/ES2332137T3/es not_active Expired - Lifetime
- 2004-06-25 AR ARP040102257A patent/AR044930A1/es not_active Application Discontinuation
-
2008
- 2008-05-22 US US12/154,319 patent/US20090253685A1/en not_active Abandoned
- 2008-10-07 US US12/247,072 patent/US20090137596A1/en not_active Abandoned
-
2009
- 2009-03-09 AR ARP090100837A patent/AR070977A2/es unknown
- 2009-04-03 JP JP2009091214A patent/JP2009149694A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514639A5 (enExample) | ||
| NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
| RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| NO20081582L (no) | Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer | |
| WO2008148868A8 (en) | Piperidine/piperazine derivatives | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
| NO20064297L (no) | Aminoalkoholforbindelse | |
| EA200401615A1 (ru) | ИНГИБИТОРЫ АКТИВАЦИИ NF-kB | |
| UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
| JP2019504050A5 (enExample) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
| MA34897B1 (fr) | Formulations d'immunosupresseurs | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| NO20082077L (no) | Spirosykliske quinazolinderivater som PDE7-inhibitorer | |
| RU2007110629A (ru) | Ингибиторы днк-пк | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| MX2011007864A (es) | Isosteros para realzar la transcripcion y su uso en terapia. | |
| MY165634A (en) | Pyrazole compounds having therapeutic effect on multiple myeloma | |
| CA2612176A1 (en) | Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors | |
| MXPA05011276A (es) | Derivado heterociclico de cinco miembros. |